Dr. Vogelzang Discusses the Cabozantinib Trial Design

Nicholas Vogelzang, MD, discusses re-emergence of dose reduced cabozantinib + alezotuzumab in aPCПодробнее

Dr. Vogelzang Discusses Cabozantinib Trial DesignПодробнее

Dr. Vogelzang Discusses Cabozantinib's Dose SizeПодробнее

Dr. Ezra Cohen Discusses the Cabozantinib EXAM TrialПодробнее

Dr. Vogelzang Describes Cabozantinib's Side EffectsПодробнее

Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients w...Подробнее

Dr. Vogelzang on XL184's Effect on Bone MetastasesПодробнее

Dr. Vogelzang Discusses Mortalities in Cabozantinib TrialПодробнее

Dr. Vogelzang on Cabozantinib Clinical Trial ResultsПодробнее

Dr. Ezra Cohen on the Efficacy and Pharmacokinetics of CabozantinibПодробнее

Dr. Vogelzang Discusses Treatment With Radium-223 and Chemotherapy for Prostate CancerПодробнее

Dr. Vogelzang Discusses PROSPECT Trial for Prostate CancerПодробнее

What is the next big thing in kidney cancer care and treatment?Подробнее

What kind of developments in kidney cancer care and treatment can we expect in the next few years?Подробнее

Dr. Posadas Gives an Analysis of a Phase II Study of Cabozantinib in mCRPCПодробнее

Clinical Rationale for Cabozantinib in HCCПодробнее

Dr. Ezra Cohen Discusses the Cabozantinib Dose Size and TolerabilityПодробнее

Dr. Tolaney on Trials Investigating Cabozantinib in Breast CancerПодробнее

Cabozantinib Plus Nivolumab for First-Line mRCCПодробнее